throbber
Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 1 of 20 PageID 1
`
`Howard L. Wernow, B.C.S.
`Florida Bar No. 0107560
`Howard.Wernow@sswip.com
`SAND, SEBOLT & WERNOW Co., LPA
`AEGIS TOWER – Suite 1100
`4940 Munson Street NW
`Canton, Ohio 44718
`Phone: 330-244-1174
`Fax: 330-244-1173
`
`Ryan E. Hatch (CA SB No. 235577)
`(Pro hac vice forthcoming)
`LAW OFFICE OF RYAN E. HATCH, PC
`13323 Washington Blvd., Suite 100
`Los Angeles, CA 90066
`Work: 310-279-5076
`Mobile: 310-435-6374
`Fax: 310-693-5328
`ryan@ryanehatch.com
`
`Attorneys for Plaintiffs
`RK Solutions, LLC, Axcess Global Sciences, LLC and Compound Solutions, Inc.
`
`IN THE UNITED STATES DISTRICT COURT
`MIDDLE DISTRICT OF FLORIDA
`TAMPA DIVISION
`
`RK SOLUTIONS, LLC, AXCESS
`Civil Action No.
`GLOBAL SCIENCES, LLC, and
`
`COMPOUND SOLUTIONS, INC.
`COMPLAINT FOR PATENT AND
`
`TRADEMARK INFRINGEMENT
` Plaintiffs,
`
`
`JURY TRIAL DEMANDED
` v.
`
`
`THE FULFILLMENT LAB, INC.,
`
` Defendant,
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 2 of 20 PageID 2
`
`COMPLAINT FOR PATENT INFRINGEMENT
`
`RK Solutions, LLC (“RK Solutions”), Axcess Global Sciences, LLC, (“AGS”)
`
`and Compound Solutions, Inc. (“Compound Solutions”) (collectively “Plaintiffs”) file
`
`their Complaint in this patent and trademark infringement action against Defendant The
`
`Fulfillment Lab, Inc. (“Defendant” or “TFL”).
`
`PARTIES
`
`1.
`
`Plaintiff RK Solutions, LLC is a Utah Limited Liability Company
`
`headquartered at 2040 East Holladay Rd, Suite 102, Holladay, UT 84117. RK Solutions
`
`is the exclusive licensee of U.S. Patent No. 6,613,356 (“the ’356 Patent” or “Patent-in-
`
`Suit”), entitled “Patent for inventions covering weight loss medication and method” (“the
`
`’356 Patent,” attached as Exhibit A).
`
`2.
`
`Plaintiff Axcess Global Sciences, LLC is a Utah Limited Liability
`
`Company with a principal place of business at 2040 East Murray Holladay Rd., Suite
`
`102, Holladay, Utah 84117. AGS is the owner and licensor of the ’356 Patent.
`
`3.
`
`Plaintiff Compound Solutions, Inc. a California corporation with a
`
`principle place of business at 1930 Palomar Point Way, # 105, Carlsbad, CA 92008.
`
`Compound Solutions is the owner of U.S. Trademark Reg. No. 86834808 for the word
`
`mark GOBHB for use in nutritional or dietary supplements (the “GOBHB Mark”). A
`
`true and correct copy of the Registration Certificate for the GOBHB Mark is attached
`
`hereto as Exhibit B.
`
`4.
`
`Defendant The Fulfillment Lab, Inc.
`
`is a Florida corporation
`
`headquartered at 5136 West Clifton St, Tampa, FL 33634. TFL may be served with
`
`
`
`2
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 3 of 20 PageID 3
`
`process by delivering a summons and a true and correct copy of this Complaint to its
`
`registered agent for receipt of service of process, Richard B. Nelson II, 5136 West Clifton
`
`St, Tampa, FL 33634.
`
`JURISDICTION AND VENUE
`
`5.
`
`This action arises under the patent and trademark laws of the United
`
`States, Titles 35 and 15 of the United States Code. Accordingly, this Court has subject
`
`matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).
`
`6.
`
`This Court has personal jurisdiction over Defendant because, among
`
`other reasons, Defendant has established minimum contacts with the forum state of
`
`Florida.
`
`7.
`
`Venue is proper in this District under 28 U.S.C. §§ 1400(b) and 1391.
`
`Defendant has committed acts of patent and trademark infringement in this District,
`
`resides in this District, and has a regular and established place of business in this District
`
`located at 5136 West Clifton St, Tampa, FL 33634.
`
`BACKGROUND
`
`8.
`
`Plaintiffs RK Solutions and AGS have the right to assert all causes of
`
`action asserted herein arising under the ’356 Patent and the right to remedies for
`
`infringement thereof.
`
`9.
`
`The inventive concepts of the ’356 Patent are generally directed to
`
`processes and compositions of matter for causing weight loss or avoidance of weight gain
`
`through oral administration of butyric acid or one or more enumerated pharmaceutically
`
`effective and acceptable salts or derivatives of butyric acid.
`
`
`
`3
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 4 of 20 PageID 4
`
`10.
`
`For example, the salts and derivates of butyric acid recited in the claims
`
`of the ’356 Patent include sodium butyrate, calcium butyrate, potassium butyrate,
`
`magnesium butyrate, alphahydroxybutyric acid, sodium alphahydroxybutyrate, calcium
`
`alphahydroxybutyrate,
`
`potassium
`
`alphahydroxybutyrate,
`
`magnesium
`
`alphahydroxybutyrate, betahydroxybutyric acid, sodium betahydroxybutyrate, calcium
`
`betahydroxybutyrate, potassium betahydroxybutyrate, magnesium betahydroxybutyrate,
`
`isobutyric acid, sodium isobutryate, calcium isobutyrate, potassium isobutyrate, and
`
`magnesium isobutyrate.
`
`11.
`
`The
`
`compounds
`
`comprising
`
`alphahydroxybutyric
`
`acid,
`
`betahydroxybutyric acid, and isobutyric acid, are derivatives of butyric acid and not salts
`
`of butyric acid.
`
`12.
`
`The remaining compounds consisting of sodium butyrate, calcium
`
`butyrate, potassium butyrate, magnesium butyrate, sodium alphahydroxybutyrate,
`
`calcium
`
`alphahydroxybutyrate,
`
`potassium
`
`alphahydroxybutyrate, magnesium
`
`alphahydroxybutyrate, betahydroxybutyric acid, sodium betahydroxybutyrate, calcium
`
`betahydroxybutyrate, potassium betahydroxybutyrate, magnesium betahydroxybutyrate,
`
`isobutyric acid, sodium isobutryate, calcium isobutyrate, potassium isobutyrate, and
`
`magnesium isobutyrate are salts of butyric acid.
`
`13.
`
`14.
`
`A compound cannot be a salt or derivative of itself.
`
`A person of skill in the art would understand the term “salts or
`
`derivatives” of butyric acid to exclude butyric acid.
`
`15.
`
`Claim 2 of the ’356 Patent recites: “The process of claim 1, wherein said
`
`
`
`4
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 5 of 20 PageID 5
`
`salts or derivatives [of butyric acid] are administered orally to said mammal in a
`
`dissolvable tablet or capsule” (emphasis added).
`
`16.
`
`Claim 2 is limited to the salts and derivatives of butyric acid and its scope
`
`does not include butyric acid.
`
`17.
`
`Similarly, claims 3 and 4, which depend from claim 2, are limited to the
`
`salts and derivatives of butyric acid and their scope does not include butyric acid.
`
`18.
`
`Claim 15 of the ’356 Patent recites: “The composition of matter in claim
`
`14, wherein the contents of the capsule further comprise sodium bicarbonate, calcium
`
`carbonate or potassium bicarbonate for producing carbon dioxide gas on contact with the
`
`stomach liquids of said mammal wherein the amount of sodium bicarbonate, calcium
`
`carbonate or potassium bicarbonate is sufficient to cause the breakup of the capsule or
`
`tablet thus releasing the salts or derivatives, but insufficient to cause distension of the
`
`stomach of the mammal.”
`
`19.
`
`Claim 15 is limited to the salts and derivatives of butyric acid and its
`
`scope does not include butyric acid.
`
`20.
`
`Similarly, claim 16, which depends from claim 15, is limited to the salts
`
`and derivatives of butyric acid and its scope does not include butyric acid.
`
`21.
`
`Claim 18 of the ’356 Patent recites: “The composition of matter of claim
`
`17, wherein the contents of said tablet further comprise sodium bicarbonate, calcium
`
`carbonate or potassium bicarbonate for producing carbon dioxide gas on contact with the
`
`stomach liquids of said mammal wherein the amount of sodium bicarbonate, calcium
`
`carbonate or potassium bicarbonate is sufficient to cause the breakup of the capsule or
`
`
`
`5
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 6 of 20 PageID 6
`
`tablet thus releasing the salts or derivatives, but insufficient to cause distension of the
`
`stomach of the mammal” (emphasis added).
`
`22.
`
`Claim 18 is limited to the salts and derivatives of butyric acid and its
`
`scope does not include butyric acid.
`
`23.
`
`Similarly, claim 19, which depends from claim 18, is limited to the salts
`
`and derivatives of butyric acid and its scope does not include butyric acid.
`
`24.
`
`On information and belief, none of the salts and derivatives of butyric
`
`acid are endogenous (i.e., occur naturally in the body of humans or other mammals),
`
`including either in the body generally or in the stomach.
`
`25.
`
`For example, the human body generally has an alkaline pH of
`
`approximately 7.4. On information and belief, the salts and derivatives of butyric acid
`
`do not exist naturally in an alkaline environment. In an alkaline environment, the
`
`hydrogen (in the case of derivatives of butyric acid) or the sodium, calcium, potassium,
`
`or magnesium ion (in the case of the salts of butyric acid) separates from the molecule
`
`(i.e., is ionized).
`
`26.
`
`On information and belief, to be useful to the body, the salts and
`
`derivatives of butyric acid must be manufactured by industrial processes and exogenously
`
`administered.
`
`27.
`
`Exogenous ingestion of salts and derivatives of butyric acid has benefits
`
`compared to butyric acid. For example, salts and derivatives of butyric acid are not
`
`odiferous, do not have a tendency to irritate the stomach, and the salts of butyric acid
`
`contain electrolytes that can replenish electrolytes lost through sweat or in the urine.
`
`
`
`6
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 7 of 20 PageID 7
`
`DEFENDANT’S BUSINESS PRACTICES
`
`28.
`
`According to its website www.thefulfillmentlab.com, TFL offers
`
`solutions including On-Demand, Global Fulfillment Sourcing, and Custom White /
`
`Private Label Solutions. By and through these services, TFL manufacturers, offers for
`
`sale, imports, and sells products, including but not limited to “Keto Boost,” “Ultra Fast
`
`Keto Boost,” “Ultra Fast Keto Boost Pro,” “Rapid Fast Keto Boost,” “Alkatone Keto
`
`Boost,” “Slim Fast Keto Boost,” products bearing similar names, and other products
`
`containing formulations of betahydroxybutyrate (“BHB”) (collectively, the “Accused
`
`Products”).
`
`29.
`
`TFL’s On-Demand services give its customers the ability to quickly add
`
`new white label and private label products to their line. TFL establishes relationships
`
`with contract manufacturers who provide TFL with products, including the Accused
`
`Products, to complement their other customer’s existing offerings. TFL thereby promotes
`
`and offers the Accused Products for sale to increase its profits. TFL intends to transform
`
`one-time buyers into repeat customers with “upsells” of the Accused Products that drive
`
`additional revenue to TFL.
`
`30.
`
`To drive revenue, TFL allows its customers to create an initial product
`
`offering, add complementary on-demand products, including on information and belief
`
`the Accused Products, create a customized label for the Accused Products, and start
`
`selling without having to purchase the products themselves or make any upfront
`
`investment. TFL thereby maintains its own supply of the Accused Products, and
`
`substantially participates in the making, offering for sale, and selling of those products.
`
`
`
`7
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 8 of 20 PageID 8
`
`TFL’s on-demand products can be white-labeled or private-labeled with customization
`
`that aligns with the Customer’s brand and meets customer needs.
`
`31.
`
`TFL also provides Global Fulfillment Sourcing Services. This allows
`
`customers to find products, get the best price, and verify the manufacturing source.
`
`Customers suggest a product category to TFL, and in turn, TFL provides customers with
`
`information about product specifications, including dosages and ingredients. TFL
`
`provides insights into the most important market trends, including average sales, sales
`
`trends, average price charged and price trends. TFL then conducts due diligence for a
`
`selected manufacturer, including review of the legal status of the company, verifying
`
`experience, and checking relevant certifications. TFL provides a detailed report including
`
`disclosure of this information.
`
`32.
`
`TFL also provides Custom White / Private Label Solutions. This permits
`
`customers to customize existing products, including on information and belief the
`
`Accused Products, to grow brands and boost profit margins. TFL offers professional
`
`manufacturing services. According to TFL, this provides benefits to customers, including
`
`“avoid[ing] intellectual property rights (IPR) infringements,” insufficient product
`
`certifications, bad customs research, and poor product quality.
`
`33.
`
`TFL also provides product and packaging mockups for customers to
`
`visualize how the design will look, and TFL takes the design to the manufacturing partner.
`
`TFL reviews white label manufacturers, compares exact product specifications, pricing,
`
`and quality so its customers don’t have to. TFL is involved in decisions regarding price
`
`and quality of the products, including the Accused Products.
`
`
`
`8
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 9 of 20 PageID 9
`
`34.
`
`TFL also provides customized samples, including of the Accused
`
`Products, so that customers experience how the product will look and feel. TFL sends a
`
`product and packaging sample that is customized with a personal design before it is
`
`available for sale.
`
`35.
`
`TFL also assures correct certifications and intellectual property rights.
`
`TFL ensures correct product certifications for importing the products, and that the
`
`products are “not infringing on any patents or intellectual property rights (IPR)” that the
`
`customer could be held liable for. TFL then starts mass production at the white label
`
`manufacturer. From start to finish, TFL states that it monitors the entire process to ensure
`
`that “everything goes smoothly.”
`
`36.
`
`Lastly, TFL provides quality control services. TFL checks every
`
`production batch at the production company twice, for any potential problems. TFL
`
`works to get the products from the factory to its own warehouse, resulting in product
`
`delivered in a timely fashion.
`
`37.
`
`On information and belief, TFL provides all of the foregoing services to
`
`at least make, offer for sale, sell, and import the Accused Products.
`
`EXEMPLARY ACCUSED PRODUCTS
`
`38.
`
`TFL makes, offers for sale, sells and imports the “Ultra Fast Keto Boost”
`
`product, also marketed under the name “Ultra Fast Pure Keto Boost.” This contains
`
`capsules containing a blend of Magnesium BHB, Calcium BHB, and Sodium BHB,
`
`among other ingredients. A serving size of two capsules contains 800 mg of the BHB
`
`blend. The label of Ultra Fast Keto Boost states “Weight Loss Support.”
`
`
`
`9
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 10 of 20 PageID 10
`
`39.
`
`TFL makes, offers for sale, sells and imports the “Keto Boost” product,
`
`also marketed under the name “Rapid Fast Keto Boost.” It contains capsules containing
`
`a blend of Magnesium BHB, Calcium BHB, and Sodium BHB, among other ingredients.
`
`A serving size of two capsules contains 800 mg of the BHB blend. Ultra Fast Keto Boost
`
`is marketed for the purpose of weight loss or avoidance of weight gain. For example, the
`
`label of Ultra Fast Keto Boost states “Advanced Weight Loss.”
`
`40.
`
`The foregoing are only examples of the Accused Products, which also
`
`include other products having similar formulations containing BHB.
`
`COUNT I
`
`INFRINGEMENT OF U.S. PATENT NO. 6,613,356
`
`41.
`
`Plaintiffs incorporate by reference each of the allegations in the
`
`foregoing paragraphs, and further allege as follows:
`
`42.
`
`On September 2, 2003, the United States Patent and Trademark Office
`
`issued the ’356 Patent for inventions generally directed to processes and compositions of
`
`matter for causing weight loss or avoidance of weight gain through oral administration
`
`of butyric acid or one or more pharmaceutically effective and acceptable salts or
`
`derivatives of butyric acid, including beta-hydroxybutyrate (“BHB”) products.
`
`43.
`
`On information and belief, Defendant has been and is directly infringing,
`
`inducing others to infringe, and/or contributorily infringing, literally, under the doctrine
`
`of equivalents, and/or jointly, one or more claims of the ’356 Patent, in the State of
`
`California, including but not limited to claims 1, 6, 7, and 14, in this District, and
`
`elsewhere in the United States by, among other things, importing, making, offering for
`
`
`
`10
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 11 of 20 PageID 11
`
`sale, and selling in the United States certain methods or systems disclosed and claimed
`
`in the ’356 Patent, including the Accused Products.
`
`44.
`
`Defendant has had knowledge of the ’356 Patent since at least the service
`
`of the Complaint in this action.
`
`45.
`
`With knowledge of the ’356 Patent, Defendant knows or should have
`
`known, and specifically intends, for the Accused Products to be used to infringe the
`
`claims of the ’356 Patent, for example by making, importing, offering to sell and selling
`
`the Accused Products, which are incorporated into capsules that Defendant knows or
`
`should have known, and specifically intends, to be orally administered for the purpose of
`
`weight loss or avoidance of weight gain.
`
`46.
`
`Defendant advertises and markets the Accused Products for purposes of
`
`weight loss and avoidance of weight gain.
`
`47.
`
`Defendant directly and indirectly infringes the ’356 Patent, including but
`
`not limited to claim 14, by offering to sell, and on information and belief also importing,
`
`making, using, and selling, on their websites and in other channels of trade, the Accused
`
`Products, which are compositions of matter comprising a capsule (e.g. capsules of the
`
`Accused Products), which are capable of dissolving in the stomach of a mammal (e.g. a
`
`human being), wherein said capsule contains, in an amount effective for weight loss or
`
`avoidance of weight gain in said mammal (e.g. Defendant markets the Accused Products
`
`for purposes of weight loss or avoidance of weight gain), one or more of the compounds
`
`selected from the group consisting of: butyric acid, sodium butyrate, calcium butyrate,
`
`potassium butyrate, magnesium butyrate, alphahydroxybutyric acid,
`
`sodium
`
`
`
`11
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 12 of 20 PageID 12
`
`alphahydroxybutyrate, calcium alphahydroxybutyrate, potassium alphahydroxybutyrate,
`
`magnesium
`
`alphahydroxybutyrate,
`
`betahydroxybutyric
`
`acid,
`
`sodium
`
`betahydroxybutyrate, calcium betahydroxybutyrate, potassium betahydroxybutyrate,
`
`magnesium betahydroxybutyrate,
`
`isobutyric acid, sodium
`
`isobutryate, calcium
`
`isobutyrate, potassium isobutyrate, and magnesium isobutyrate (e.g., the Accused
`
`Products include sodium betahydroxybutyrate, calcium betahydroxybutyrate, and
`
`magnesium betahydroxybutyrate), according to claim 14 of the ’356 Patent.
`
`48.
`
`Additional direct infringers of the ’356 Patent claims include but are not
`
`limited to end-users who use the Accused Products in processes for causing weight loss
`
`or avoidance of weight gain in mammals (e.g. according to claims 1, 6 and 7), including
`
`Defendant’s customers, the specific identities of which are not known at this time;
`
`Defendant and any other individuals who incorporate or offer to sell, or import, make,
`
`use, or sell, the Accused Products incorporated into capsules capable of dissolving in the
`
`stomach of a mammal (e.g. according to claim 14), including Defendant and Defendant’s
`
`customers, the identities of which are not known at this time (collectively, the
`
`“Defendant’s Customers”).
`
`49.
`
`In addition to these examples of direct infringement, Defendant has also
`
`been and is inducing and/or contributing to the direct infringement of the ’356 Patent by
`
`at least, but not limited to, customers of Defendant, partners of Defendant, and/or end-
`
`users of Defendant’s products including the Defendant’s Customers, including those who
`
`directly practice, implement, use or otherwise participate in the use of the Accused
`
`Products, which have no substantial non-infringing uses, by at least the following
`
`
`
`12
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 13 of 20 PageID 13
`
`affirmative acts: (1) advertising and marketing the features, benefits and availability of
`
`the Accused Products; (2) promoting the adoption and use of the Accused Products; and
`
`(3) providing instructions on how to use the Accused Products. Such activity includes,
`
`but it not limited to, the activities pertaining to Defendant’s On-Demand, Global
`
`Fulfillment Sourcing, and Custom White / Private Label Solutions as discussed above,
`
`and incorporated herein by reference.
`
`50.
`
`Defendant
`
`indirectly
`
`infringes by actively, knowingly, and/or
`
`intentionally inducing or contributing to infringement of one or more of the claims of the
`
`’356 Patent, including claims 1, 6, 7 and 14, by third parties including the Defendant’s
`
`Customers, who directly implement, use or otherwise participate in the use of the
`
`Accused Products. On information and belief, Defendant actively, knowingly, and/or
`
`intentionally induces the use of the Accused Products by third parties including the
`
`Defendant’s Customers, and provides or otherwise implement material components of
`
`one or more claims of the ’356 Patent, including, but not limited to, claims 1, 6, 7, 14 and
`
`17, which were especially made or adapted for use in the infringement of the ’356 Patent
`
`claims, and are not a staple article or commodity of commerce suitable for substantial
`
`non-infringing uses. Defendant knows and has known that the combination for which
`
`their infringing Accused Products were especially made or adapted are both patented and
`
`infringing.
`
`51.
`
`Defendant also at least indirectly infringes claims 1, 6, 7, and 14 of the
`
`’356 Patent. Defendant’s indirect infringement is based on direct infringement of third
`
`parties including but not limited to Defendant’s customers and end-users of the Accused
`
`
`
`13
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 14 of 20 PageID 14
`
`Products, whose identities are not known at this time.
`
`52.
`
`For example, end-users of the Accused Products directly infringe the
`
`’356 Patent, including but not limited to claim 1, by practicing a process for causing
`
`weight loss, or avoidance of weight gain (e.g. Defendant promotes the Accused Products
`
`as beneficial for “weight loss”) in mammals (e.g. humans), comprising oral
`
`administration (e.g. the Accused Products are capsules or tablets that are orally
`
`administered) to said mammals of butyric acid or one or more pharmaceutically effective
`
`and acceptable salts or derivatives of butyric acid selected from the group consisting of:
`
`butyric acid, sodium butyrate, calcium butyrate, potassium butyrate, magnesium butyrate,
`
`alphahydroxybutyric
`
`acid,
`
`sodium
`
`alphahydroxybutyrate,
`
`calcium
`
`alphahydroxybutyrate,
`
`potassium
`
`alphahydroxybutyrate,
`
`magnesium
`
`alphahydroxybutyrate, betahydroxybutyric acid, sodium betahydroxybutyrate, calcium
`
`betahydroxybutyrate, potassium betahydroxybutyrate, magnesium betahydroxybutyrate,
`
`isobutyric acid, sodium isobutryate, calcium isobutyrate, potassium isobutyrate, and
`
`magnesium isobutyrate (e.g., the Accused Products include sodium betahydroxybutyrate,
`
`calcium betahydroxybutyrate, and magnesium betahydroxybutyrate).
`
`53.
`
`End-users of the Accused Products also directly infringe the ’356 Patent,
`
`including but not limited to claim 6. Defendant’s instructions for the Accused Products
`
`are to take doses of 800 mg of BHB blend per day, which for the average adult surface
`
`area of 1.6 square meters, results in 500 mg per square meter of body surface per day.
`
`These doses are between 60 mg and 900 mg per square meter of body surface as provided
`
`in claim 6.
`
`
`
`14
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 15 of 20 PageID 15
`
`54.
`
`End-users of the Accused Products also directly infringe the ’356 Patent,
`
`including but not limited to claim 7. For example, end-users of the Accused Products
`
`directly infringe the ’356 Patent claim 7, because Defendant’s instructions for the
`
`Accused Products are to take a dose of 800 mg, which could fall within the limits set forth
`
`in claim 7. One daily dose of 800mg for a person having a surface area of 0.88 square
`
`meters or less results in a dose of over 900 mg/m2. This dosage would be within the range
`
`of greater than 0.9 grams and equal to or less than 4.7 grams (or 2.35 grams for
`
`magnesium salts) per square meter of body surface area per day, as recited in claim 7.
`
`55.
`
`Defendant has committed these acts of infringement without license or
`
`authorization.
`
`56.
`
`Defendant has injured Plaintiffs and are liable to Plaintiffs for direct and
`
`indirect infringement of the claims of the ’356 Patent pursuant to 35 U.S.C. § 271(a), (b),
`
`and (c).
`
`57.
`
`As a result of Defendant’s infringement of the ’356 Patent, Plaintiffs
`
`have suffered harm and seek injunctive relief and monetary damages in an amount
`
`adequate to compensate for infringement, but in no event less than a reasonable royalty
`
`for the use made of the invention by Defendant, together with interest and costs as fixed
`
`by the Court.
`
`TRADEMARK INFRINGEMENT UNDER 15 U.S.C. § 1114
`
`58.
`
`Plaintiffs incorporate by reference each of the allegations in the
`
`foregoing paragraphs, and further allege as follows:
`
`59.
`
`The GOBHB Mark is valid and protectable, and Federal registration of
`
`
`
`15
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 16 of 20 PageID 16
`
`the GOBHB Mark provides prima facie evidence of validity and protectability.
`
`60.
`
`The GOBHB Mark is also distinctive. As a Federally-registered mark,
`
`the GOBHB Mark, is presumed to be distinctive.
`
`61.
`
`Defendant is a provider of sales, marketing, warehouse, manufacturing,
`
`bottling, packaging and shipping services, including for nutritional and dietary
`
`supplements.
`
`62.
`
`On information and belief, Defendant regularly uses the GOBHB Mark
`
`in United States commerce in connection with promoting its own goods and services
`
`including but not limited to in connection with the “Rapid Fast Keto Boost” product, e.g.:
`
`
`
`See https://www.amazon.com/ULTRA-KETO-Rapid-Fast-Boost/dp/B083G6PR5J,
`
`visited April 6, 2020
`
`63.
`
`Defendant has committed these acts without license or authorization
`
`
`
`16
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 17 of 20 PageID 17
`
`from Compound Solutions.
`
`64.
`
`Based on Defendant’s unauthorized use of the GoBHB Mark, consumers
`
`are likely to be confused as to the source or sponsorship of Defendant’s products and
`
`services.
`
`65.
`
`Defendant had at least statutory notice that the GOBHB Mark was
`
`registered.
`
`66.
`
`Defendant’s activities as stated herein constitute false designation of
`
`origin and trademark infringement in violation of 15 U.S.C. §1114(1)(a).
`
`67.
`
`Defendant’s activities as alleged herein constitute a violation of 15
`
`U.S.C. § 1114(1)(b) in that Defendant has, without the consent of Compound Solutions,
`
`used in commerce a counterfeit, copy, or colorable imitation of the registered mark of
`
`Compound Solutions and applied such counterfeit, copy, or colorable imitation to
`
`advertisements intended to be used in commerce, in connection with the sale, offering for
`
`sale, distribution or advertising of goods or services. Defendant has used the imitation of
`
`the GOBHB Mark in such a manner as is likely to cause confusion, mistake or to deceive.
`
`68.
`
`Defendant’s acts were committed with knowledge that the use of the
`
`BHB Mark was intended to be used to cause confusion, mistake or to deceive.
`
`69.
`
`Compound Solutions is entitled to injunctive relief under 15 U.S.C. §
`
`1116 and recovery of damages from Defendant pursuant to 15 U.S.C. § 1117. Damages
`
`recoverable include three times the actual damages sustained by Compound Solutions,
`
`Defendant’s profits and the costs of the action, together with Compound Solutions’
`
`attorney fees, damages in such sum as the court may find to be just according to the
`
`
`
`17
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 18 of 20 PageID 18
`
`circumstances of the case, and statutory damages.
`
`70.
`
`Upon information and belief, Defendant’s wrongful activities have
`
`caused, and unless enjoined by this Court will continue to cause, irreparable injury and
`
`other damage to Compound Solutions’ business, reputation and goodwill in the industry.
`
`Compound Solutions has no adequate remedy at law.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiffs respectfully pray for entry of judgment as follows:
`
`1.
`
`That Defendant has directly and indirectly infringed one or more
`
`claims of the ’356 Patent;
`
`2.
`
`3.
`
`That Defendant be ordered to provide an accounting;
`
`That Plaintiffs are entitled to, and should recover, all damages to which
`
`they are entitled under 35 U.S.C. § 284, but in no event less than a reasonable royalty;
`
`4.
`
`That Plaintiffs, as the prevailing party, shall recover from Defendant all
`
`taxable costs of Court;
`
`5.
`
`That Plaintiffs shall recover from Defendant all pre- and post-judgment
`
`interest on the damages award, calculated at the highest interest rates allowed by law;
`
`6.
`
`That Plaintiffs are entitled to enhanced damages of up to three times
`
`the amount found by the jury or ordered by the Court, pursuant to 35 U.S.C. § 284;
`
`7.
`
`That this case is exceptional and that Plaintiffs shall therefore recover
`
`their attorneys’ fees and other recoverable expenses, pursuant to 35 U.S.C. § 285;
`
`8.
`
`That Defendant is permanently enjoined from further infringement of
`
`the ’356 Patent;
`
`
`
`18
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 19 of 20 PageID 19
`
`9.
`
`10.
`
`An order finding that Defendant is liable for trademark infringement;
`
`For actual and compensatory damages in an amount to be proven at
`
`trial, including but not limited to Defendant’s profits, damages sustained by Compound
`
`Solutions, statutory damages, and costs of this action;
`
`11.
`
`A preliminary and permanent injunction enjoining Defendant and all of
`
`its officers, directors, customers, suppliers, distributors, agents, end-users, and other
`
`personnel from using the GOBHB Trademark in commerce without authorization;
`
`12.
`
`That Plaintiffs, as the prevailing party, shall recover from Defendant all
`
`taxable costs of Court; and
`
`13.
`
`Such other and further relief as the Court deems appropriate.
`
`JURY TRIAL DEMANDED
`
`Pursuant to Rule 38 of the Federal Rules of Civil Procedure, Plaintiffs request a
`
`trial by jury of any issues so triable by right.
`
`///
`
`///
`
`///
`
`///
`
`///
`
`///
`
`///
`
`
`
`
`
`
`
`19
`
`

`

`Case 8:20-cv-01072-MSS-CPT Document 1 Filed 05/08/20 Page 20 of 20 PageID 20
`
`Dated: May 8, 2020
`
`
`
`Respectfully submitted,
`
`/s/ Howard L. Wernow
`Howard L. Wernow, B.C.S.
`Florida Bar No. 0107560
`SAND, SEBOLT & WERNOW Co., LPA
`AEGIS TOWER – Suite 1100
`4940 Munson Street NW
`Canton, Ohio 44718
`Phone: 330-244-1174
`Fax: 330-244-1173
`Howard.Wernow@sswip.com
`
`Ryan E. Hatch
`(Pro hac vice forthcoming)
`LAW OFFICE OF RYAN E. HATCH, PC
`13323 Washington Blvd., Suite 100
`Los Angeles, CA 90066
`Work: 310-279-5076
`Mobile: 310-435-6374
`Fax: 310-693-5328
`ryan@ryanehatch.com
`
`Attorneys for Plaintiffs RK Solutions, LLC, Axcess
`Global Sciences, LLC and Compound Solutions,
`Inc.
`
`
`
`
`
`20
`
`
`
`
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket